Optimizing ART With Novel HIV Agents
Update: 2024-08-16
Description
In this episode, Gregory Huhn, MD, MPHTM, presents a case study of a person with a long HIV treatment history, exploring when and how to consider agents with novel mechanisms of action.
Listen as he discusses:
- The importance of engaging with patients to understand their perspectives and improve their satisfaction with their HIV care
- Options in people with multiclass resistance
- Studies of agents with novel mechanisms of action:
- BRIGHTE (fostemsavir)
- TMB-301/-311 (ibalizumab)
- CAPELLA (lenacapavir)
Faculty
Gregory Huhn, MD, MPHTM,
Interim Chief, Division of Infectious Diseases
Senior Director of HIV Services
Cook County HIV Integrated Programs
Interim Medical Director, The RMR CORE Center
Professor, Division of Infectious Diseases
Rush University Medical Center
Chicago, Illinois
Follow along with the slides.
https://bit.ly/4fHmxg5
Get access to all of our new podcast episodes. Subscribe to the CCO Infectious Disease podcast on Apple Podcasts, Google Podcasts, or Spotify.
Comments
Top Podcasts
The Best New Comedy Podcast Right Now – June 2024The Best News Podcast Right Now – June 2024The Best New Business Podcast Right Now – June 2024The Best New Sports Podcast Right Now – June 2024The Best New True Crime Podcast Right Now – June 2024The Best New Joe Rogan Experience Podcast Right Now – June 20The Best New Dan Bongino Show Podcast Right Now – June 20The Best New Mark Levin Podcast – June 2024
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
